MAMaria D. Ardatskaya

Maria D. Ardatskaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maria D. Ardatskaya has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rome Criteria for irritable bowel syndrome, fifth revision: Key updates. A review

    by Tatiana B. Topchii, Топчий Татьяна Борисовна, Maria D. Ardatskaya, Ардатская Мария Дмитриевна, Leonid V. Maslovskii, Масловский Леонид Витальевич, Oleg N. Minushkin, Минушкин Олег Николаевич, Igor V. Zverkov, Зверков Игорь Владимирович

    The Rome V Criteria, published in 2026, updates the scientific and clinical understanding of irritable bowel syndrome (IBS). It redefines IBS from a “functional disorder” to a “gut-brain interaction disorder,” emphasizing biological underpinnings. Recognized pathophysiological mechanisms include impaired motility, alterations in the microbiota and its metabolites, immune dysregulation, serotonin modulation, increased intestinal permeability, visceral hypersensitivity, and bile acid malabsorption. The updated criteria define IBS as recurrent abdominal pain and/or discomfort associated with changes in bowel habits, such as constipation, diarrhea, or a mixed pattern, with symptoms present for at least six months prior to diagnosis and persisting during the preceding three months. Notable updates include the reintroduction of “abdominal discomfort,” a reduced pain frequency threshold of at least three days per week, clarification that pain or discomfort should not be constant, and an auxiliary criterion specifying that pain or discomfort should not be exclusively related to menstruation. IBS is now classified into four primary subtypes based on predominant stool patterns, as determined by the Bristol Stool Form Scale: IBS with constipation, IBS with diarrhea, IBS with mixed bowel habits, and IBS with unclassified bowel habits. Diagnosis is based on typical symptoms in the absence of alarm features, and IBS is no longer considered a diagnosis of exclusion. The revised diagnostic algorithm involves sequential clinical assessment, targeted use of a limited set of laboratory and instrumental tests, and explicit criteria for further evaluation. The Rome V Criteria also recommend a stepwise approach to IBS therapy, including lifestyle and dietary modifications, pharmacological management of predominant symptoms, and behavioral interventions targeting brain-gut axis interactions.

  • Open Access

    Experimental, metabolic, and clinical aspects of the use of metaprebiotics

    by M. D. Ardatskaya, A. M. Kolodkin, М. Д. Ардатская, А. М. Колодкин

    Disorders of the intestinal microbiocenosis are considered to be one of the pathogenetic mechanisms of the occurrence and progression of not only diseases of the gastrointestinal tract, but also other diseases, exactly oncological, allergic, autoimmune, dermatological, neurological, neuropsychiatric and metabolic disorders. Modern methods, in particular, genomic sequencing, have revealed a large number of previously unknown species and genera of the intestinal microbiota, the role of which is only beginning to be clarified. In this regard, the metabolic activity of the microbiota is currently becoming increasingly important. The main metabolites of a healthy microbiota are short-chain fatty acids, which have metabolic and regulatory effects on both the host and the microbiota itself. There are various tools for correcting the microbiota, such as probiotics, prebiotics, and metabiotics. The combination of probiotics and prebiotics in symbiotics aims to improve their properties. This review focuses on the combination of the metabiotics calcium lactate and the prebiotics inulin and oligofructose. This combination can be considered as a separate subclass of agents metaprebiotic with a synergistic effect on the microbiota. The article examines the experimental effect of calcium lactate on colonization resistance, the protective effect on the normal microbiota, and the rate of restoration of the host microbiota in antibiotic-induced dysbiosis in animals. The article also evaluates the effect of a metaprebiotic on the metabolic function of the microbiota in patients with functional bowel disorders. The clinical efficacy of metaprebiotic use on symptoms and stool frequency has been demonstrated in patients with functional bowel disorders of different ages, as well as in dermatological diseases.

  • Open Access

    Restoration of microbiota balance using spore-forming probiotic microorganisms: a review

    by Maria D. Ardatskaya, Grigory V. Garushyan, Ардатская Мария Дмитриевна, Гарушьян Григорий Валерьевич

    Intestinal dysbiosis is a common condition associated with a wide range of diseases. Choosing the optimal probiotic therapy remains challenging due to the variety of available strains. Spore-forming probiotics, particularly Bacillus clausii, exhibit high resistance to aggressive gastrointestinal factors and can rapidly restore the gut microbiota. Aim – to summarize current data on the mechanisms of action and clinical efficacy of B. clausii in correcting dysbiotic disorders. A review of recent literature was performed, including systematic reviews, randomized controlled trials, real-world studies (PEGASO), and preclinical studies focusing on B. clausii. B. clausii exerts antagonistic, immunomodulatory, and metabolic effects, and restores intestinal barrier function. According to a systematic review (C. Acosta-Rodríguez-Bueno et al., 2022), a 7-day course of B. clausii significantly reduces the duration of acute diarrhea by 1–2 days and decreases the risk of antibiotic-associated diarrhea by 47–60%. In a prospective study (H. Dang et al., 2024) in children with persistent diarrhea, symptom resolution was achieved in 87.5% of patients by day 7, along with a decrease in fecal calprotectin and an increase in secretory IgA levels. In real-world practice (PEGASO study, С. Giua et al., 2024), 89% of patients rated the efficacy as “good” or “excellent,” adherence to the 7-day course was 94%, and the incidence of adverse events was 2.1%. An experimental study (M. Salem et al., 2025) revealed suppression of the TXNIP/NLRP3 inflammasome cascade and restoration of the gut microbiota following B. clausii treatment in a colitis model. B. clausii is a universal means of primary correction of dysbiosis, capable of restoring the gut microbiota and resolving diarrhea within 7 days. Owing to its transient persistence, after the course the residual disturbances can be objectively assessed, allowing for personalized therapy with other probiotics (lactobacilli, bifidobacteria, Saccharomyces boulardii, etc.) depending on the remaining alterations of the gut microbiota.

  • Features of the gut microbiota metabolism and their relationship with the parameters of the lipid profile in patients with type 2 diabetes mellitus receiving tableted hypoglycemic therapy

    by T. Yu. Demidova, A. S. Teplova, M. D. Ardatskaya

       Introduction. Gut microbiota (GM) metabolism in patients with type 2 diabetes mellitus (T2DM) has a number of features, including changes in the functional characteristics of microorganisms and, as a result, changes in the levels of the main metabolites of GM – short-chain fatty acids (SCFA).    The purpose of the study. To investigate the features of the SCFA in patients with T2DM receiving innovative hypoglycemic therapy combined with metformin.   Materials and methods.  The study included 80 patients with T2DM aged 45–60 years, with the duration of the disease to 5 years, HbA1c did not exceed 7.5 %, BMI was 27–35 kg/m 2 . All patients received metformin and SGLT-2 inhibitors or metformin and DPP-4 inhibitors.    Results. The median age of the patients was 55 [52-57] years, and the median duration of T2DM was 2 [1-4] years. The average BMI in the group was 31.22 ± 2.42 (95 % CI: 30.68–31.76) kg/m 2 . The average HbA1c level – 6.16 ± 0.79 (95 % CI: 5.98–6.33) %. A significant decrease in the level of the amount of SCFA (3,664 [2,053–7,014] mg/g) was revealed compared with the people without T2DM (10.5 ± 1.5 mg/g). The absolute concentrations of acetic, propionic, and butyric acids are also almost threefold reduced (1.93 [0.95–3.99] mg/g, 0.82 [0.39–1.58] mg/g, 0.55 [0.30–1.31] mg/g). The anaerobic index was shifted towards sharply negative values and amounted to -0.76 ± 0.25 (95 % CI: from -0.81 to -0.70). There were no statistically significant differences between the treatment groups of patients.    Conclusions.  The data obtained highlight the unresolved problem of decompensation of the microbiotic link in the pathogenesis of T2DM.

  • Open Access

    The Evolution of the gut dysbiosis theory

    by M. D. Ardatskaya, O. N. Minushkin

    Ince the discovery of microorganisms, the question of the role and mechanisms of the effect of microflora on the human body has constantly arisen. Views on the microbiota varied depending on the level of its scientific knowledge. The article examines the historical formation and current state of the gut dysbiosis theory. Aim of investigation. To trace the evolution of the gut dysbiosis theory, to summarize modern ideas about the composition, functions and role of the microbiota in maintaining human health, as well as to analyze methods for the diagnosis and correction of microbial balance disorders. Materials and methods. An analytical review of domestic and foreign literature sources on the problem of microbiocenosis has been conducted, including historical data, the results of fundamental and clinical research, as well as a comparative analysis of modern methods for diagnosing gut microbial ecology disorders, including molecular genetic and metabolomic approaches. Results. It has been established that the development of the gut dysbiosis theory has passed through several stages - from the heuristic to the analytical, reflecting the deepening of knowledge about the symbiotic interactions of humans and the microbiota. The main functions of the microbiota (energy supply, immunomodulation, vitamin synthesis, protection against pathogens) have been determined. Classifications and criteria of dysbiosis are presented, modern diagnostic methods are proposed, including gas-liquid chromatography of short-chain fatty acids, which is highly informative. The principles of correction of microbiocenosis disorders using probiotics, prebiotics, synbiotics and metabiotics are substantiated, and the effectiveness of individualized treatment regimens is shown. Conclusion. The modern gut dysbiosis theory is based on the understanding of the microbiota as a full-fledged “metabolic organ”, closely integrated with the macroorganism. The development of molecular and metabolic technologies opens up prospects for personalized medicine, early diagnosis and targeted correction of microecological disorders. Further research should be aimed at studying the mechanisms of interaction of the microbiota with various body systems and developing targeted therapeutic strategies.


  • Effectiveness of synbiotic biocomplexes in correction of gut microbiocenosis disorders

    by M. D. Ardatskaya, I. V. Zverkov, L. V. Maslovskii, T. B. Topchiy, O. N. Minushkin

    The state of the gut microbiota largely determines the course of pathological processes in the human body. Currently, there is no doubt about the role of dysbiosis in the development and progression of many disorders, including intestinal infections, IBS, IBD, SIBO, diverticular disease, celiac disease, cancer, food intolerance, allergies, liver and pancreatic diseases, obesity, diabetes, metabolic syndrome, hematological, cardiological, genitourinary, rheumatological, neurological and neuropsychiatric. The development of tools that correct the imbalance of the gut microbiota is one of the most promising areas of the modern science. Methods for diagnosing disorders of the gut microbiota are also being improved. The importance and expediency of including agents that modulate the state of the gut microbiota in the complex therapy of many diseases is confirmed by numerous foreign and domestic studies. The evolution of probiotic products has progressed from single-strain formulations containing one type of microorganism to modern multi-strain synbiotic complexes that combine probiotics and prebiotics. The first generations of probiotics were primarily aimed at replenishing beneficial bacteria, whereas contemporary biocomplexes exert multi-level effects – they regulate the composition and activity of the gut microbiocenosis, promote the synthesis of necessary bacterial metabolites, improve intestinal barrier function, and modulate the immune response. This review article is devoted to evaluating the effectiveness of synbiotic biocomplexes Normoflorin L, B, and Д in the correction of gut microbiocenosis disorders in antibacterial therapy, functional bowel diseases, inflammatory bowel diseases, chronic pancreatitis, celiac disease, metabolic disorders and obesity, diseases of the ENT organs, dermatological and gynecological diseases.


  • Open Access

    Combination of non-alcoholic fatty liver disease and cholelithiasis: Pathophysiological and clinical relationships and specific features of therapy. A review

    by Tatiana B. Topchii, Maria D. Ardatskaya, Leonid V. Maslovskii, Oleg N. Minushkin, Топчий Татьяна Борисовна, Ардатская Мария Дмитриевна

    Non-alcoholic fatty liver disease (NAFLD) and cholelithiasis (CL) are widespread diseases worldwide. The combination of NAFLD and CL is a common clinical situation. CL and NAFLD have common risk factors and are closely associated with such concomitant diseases as obesity, dyslipidemia, and carbohydrate metabolism disorders. Numerous studies in different populations have shown that NAFLD is an independent risk factor for CL, and CL is an independent risk factor for NAFLD. Insulin resistance is now being considered as a key link between NAFLD and the development of cholesterol cholelithiasis. In addition, changes in the expression of transcription factors, including hepatic X-receptor, farnesoid X-receptor, and membrane bile acid receptors, play an important role. It leads to increased lipogenesis in the liver and to bile cholesterol supersaturation, contributing to the development of gallstones and fatty liver. An equally important role in the pathogenesis of both diseases is played by gallbladder dysfunction, which serves as an important link between the liver and the intestine within the hepatic-gallbladder-intestinal axis and supports the metabolic homeostasis of cholesterol, triglycerides, and bile acids. It is supported by evidence that cholecystectomy increases the risk of NAFLD, contributes to insulin resistance, and promotes fat accumulation in the liver. The choice of drug therapy in patients with a combination of NAFLD and CL is based on knowledge of the general pathophysiological processes typical of both diseases. Drugs should comply with the principles of multipurpose monotherapy, targeting as many therapeutic targets as possible, and their combination should potentiate each other’s pharmacological effects. The treatment of patients with a combination of NAFLD and CL is primarily based on weight loss through exercise and a Mediterranean diet, enhanced by psyllium-containing agents and butyric acid, a key mediator of the Mediterranean diet’s positive effects. The drug of choice in patients with a combination of NAFLD and CL is ursodeoxycholic acid, exerting a pathogenetic effect on both diseases.

  • Open Access

    The role of synbiotics in correcting gut microbiota disorders and increased intestinal permeability: A review

    by Maria D. Ardatskaya, Ардатская Мария Дмитриевна

    The gut microbiota participates in all metabolic processes in the human body, and its state determines the course of pathological processes. Intestinal infections, IBS, IBD, SIBO, diverticular disease, celiac disease, cancer, food intolerance, allergies, liver and pancreatic diseases, obesity, diabetes, metabolic syndrome, hematological, cardiological, genitourinary, rheumatological, neurological, neuropsychiatric and other disorders are associated with dysbiosis and increased permeability of the intestinal barrier. The means of correcting the gut microbiota are constantly being improved. The importance and expediency of using pro- and prebiotics as part of the complex therapy of many diseases is currently confirmed not only by large international clinical studies, but also by modern methods of diagnosing microbiota disorders. The review article presents clinically confirmed data on the effectiveness of the use of synbiotic Maxilac® for the correction of gut microbiota disorders and increased intestinal permeability in infectious diseases, postCOVID syndrome, IBS, including post-infectious IBS, as well as in severe atopic dermatitis in children.


  • Open Access

    Chronic constipation: current options of pathogenetic therapy

    by M. D. Ardatskaya, L. I. Butorova, A. A. Anuchkin, I. N. Gaivoronsky, A. I. Pavlov, O. Yu. Patsenko, О. Ю. Паценко

    Symptoms of constipation such as derangements of the motor, secretory and/or evacuation functions of the colon are recorded occasionally or for a long period in at least 20% of the population in economically developed countries. QoL is significantly impaired in patients with chronic constipation. The frequency, time of bowel movement and stool consistency is, in large part, determined by the motor function of the colon. The primary approach to the treatment algorithm for chronic constipation (CC) is modification of a lifestyle and a diet rich in dietary fiber. If dietary measures provide poor efficacy, laxatives are prescribed to the patients. According to the current guidelines, therapeutic approaches to the treatment of CC should include the sequential administration of laxatives that increase the volume of contents and stimulate the motor function of the colon. According to the Russian Gastroenterological Association guidelines for the diagnosis and treatment of chronic diseases in adult patients, it is reasonable to use stimulant laxatives as second-line drugs. Contact laxatives, which increase intestinal peristalsis due to stimulation of nerve endings in the intestinal mucosa, have been shown to be more effective in treating chronic constipation than placebo. Among the drugs in this group, Bisacodyl®, a diphenylmethane derivative, and Regulax® Picosulfate, a sodium picosulfate derivative, are the most studied ones. These substances are hydrolyzed into bis-(p-hydroxyphenyl)-pyridyl-2-methane in the intestine, which, on contact with the receptors in colonic mucosa, stimulates propulsive activity and increases intestinal secretions. Regulax® Picosulfate is effective and safe in patients with acute and chronic constipation of various origin.


  • Open Access

    The role of short-chain fatty acids in the formation of non-alcoholic fatty liver disease in children: A review

    by Olesya V. Pervishko, Maria D. Ardatskaya, Irina N. Zakharova, Natalia G. Soboleva, Ulyana A. Stinskaya, Irina V. Berezhnaya, Svetlana N. Borzakova, Diana K. Dmitrieva, Ардатская Мария Дмитриевна, Стинская Ульяна Александровна

    This review examines scientific publications that describe the main properties of microbiota metabolites and their participation in the pathogenetic connection of the intestinal-liver system in children with non-alcoholic fatty liver disease (NAFLD). Normal metabolism of short-chain fatty acids (SCFA) is one of the main conditions for maintaining microbiocinosis, eliminating the main pathological trigger factors. Changes in the qualitative and quantitative characteristics of SCFA can play a significant role in the development of complications in NAFLD. Studying the role of SCFAs in NAFLD in childhood will answer questions about their participation in the main links in the pathogenesis of metabolic and cardiovascular diseases, such as type 2 diabetes, dyslipidemia, hypertension and atherosclerosis. The data obtained are necessary for the development of personalized correction of the species composition of microorganisms and their metabolites at the initial stages of the disease before the development of significant fibrogenesis.